SIPs under regular plan shows better longevity
SIPs under regular plan shows better longevity

SIPs under regular plan shows better longevity

DSIJ Intelligence Article rating: 3.8

The data of the Association of Mutual Funds in India (AMFI) shows that a regular plan dominates the SIP and has better longevity than a direct plan. Read onto find out more.

Welspun India targets US markets with Target Corporation, board approves buyback & much more!
Welspun India targets US markets with Target Corporation, board approves buyback & much more!

Welspun India targets US markets with Target Corporation, board approves buyback & much more!

DSIJ Intelligence Article rating: 4.7

In a press release, Welspun India stated that the company is set to work with Target Corporation in the USA to achieve business growth. Reacting to the announcements made post the meeting held of its board of directors, its stock jumped by more than 11 per cent. 

Buzzing stock: UPL zooms more than 8 per cent
Buzzing stock: UPL zooms more than 8 per cent

Buzzing stock: UPL zooms more than 8 per cent

DSIJ Intelligence Article rating: 4.3

The shares of UPL Ltd climbed over 8 per cent on Friday, touching its 52-week high of Rs 764.45 per share, after JP Morgan released a coverage report on the company, highlighting its growth potential. 

Alembic Pharmaceuticals plunge despite getting USFDA nod for Lurasidone Hydrochloride tablets
Alembic Pharmaceuticals plunge despite getting USFDA nod for Lurasidone Hydrochloride tablets

Alembic Pharmaceuticals plunge despite getting USFDA nod for Lurasidone Hydrochloride tablets

DSIJ Intelligence Article rating: 3.7

Alembic Pharmaceuticals Limited, a leading pharmaceutical company, announced today that it has received approval from US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Lurasidone Hydrochloride tablets (20 mg, 40 mg, 60 mg, 80 mg, and 120 mg).  

Dr Reddys rolls out Sputnik-V vaccine in Indian market; priced at Rs 948 per dose
Dr Reddys rolls out Sputnik-V vaccine in Indian market; priced at Rs 948 per dose

Dr Reddys rolls out Sputnik-V vaccine in Indian market; priced at Rs 948 per dose

DSIJ Intelligence Article rating: 4.5

Dr Reddy’s Laboratories on Friday announced that the first consignment of imported doses of Sputnik-V vaccine was administered in Hyderabad today as part of a limited pilot soft-launch. The consignment of doses that landed in India on May 01, 2021, received regulatory clearance from Central Drugs Laboratory (CDL, Kasauli) on May 13, 2021.   

RSS
First24992500250125022504250625072508Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR